Recent Comments

Comment RSS

Myelin News and Research RSS Feed - Myelin News and Research

Myelin is the fatty substance that covers and protects nerves.

Experimental drug to restore function of nerves damaged in spinal cord injuries shows promise

20. November 2009 00:04
Researchers have shown how an experimental drug might restore the function of nerves damaged in spinal cord injuries by preventing short circuits caused when tiny "potassium channels" in the fibers are exposed. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , ,

Permalink | Comments (0)

UCLA study: Structural changes in brain may help offset vision loss and strengthen other senses

19. November 2009 06:30
Visually impaired people appear to be fearless, navigating busy sidewalks and crosswalks, safely finding their way using nothing more than a cane as a guide. The reason they can do this, researchers suggest, is that in at least some circumstances, blindness can heighten other senses, helping individuals adapt. [More]

Posted in: Medical Science News | Medical Condition News

Tags: , , , ,

Permalink | Comments (0)

Assessing the neurology market and its major players

17. November 2009 04:13
Research and Markets (http://www.researchandmarkets.com/research/63cb3f/dealmaking_and_ind) has announced the addition of Decision Resources, Inc.'s new report "Dealmaking and Industry Outlook: Neurological Disease" to their offering. [More]

Posted in: Medical Condition News

Tags: , , , , , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Phase II clinical study to evaluate Nanocort commenced

17. November 2009 03:22
Galapagos NV announced today that it has started a Phase II clinical study to evaluate Nanocort's effectiveness in treating flares in multiple sclerosis (MS). Nanocort combines less frequent treatment with lower dosage and potentially more effective delivery than other MS flare treatments. [More]

Posted in: Drug Trial News

Tags: , , , , , , , , , , , ,

Permalink | Comments (0)

Patients with pediatric-onset MS develop disabilities at a slower pace than patients with adult-onset MS: Study

17. November 2009 01:07
Magnetic resonance images (MRI) of patients diagnosed with multiple sclerosis in childhood show that pediatric onset multiple sclerosis is more aggressive, and causes more brain lesions, than MS diagnosed in adulthood, researchers at the University at Buffalo have reported. [More]

Posted in: Child Health News | Medical Condition News

Tags: , , , , , , ,

Permalink | Comments (0)

Transplantation of hESC-derived OPCs spare spinal cord tissue in the cervical lesion site: Study

12. November 2009 03:47
Geron Corporation today announced the publication of data showing that oligodendrocyte progenitor cells (OPCs) derived from human embryonic stem cells (hESCs), when transplanted into a rodent model of cervical spinal cord injury, reduced tissue damage within the lesion and improved recovery of locomotor function. [More]

Posted in: Medical Science News

Tags: , , , , , , , , , , ,

Permalink | Comments (0)

FDA approved stem cell therapy restores limb function in rats with neck spinal cord injuries

10. November 2009 01:02
The first human embryonic stem cell treatment approved by the FDA for human testing has been shown to restore limb function in rats with neck spinal cord injuries - a finding that could expand the clinical trial to include people with cervical damage. [More]

Posted in: Medical Science News

Tags: , , , , , , , ,

Permalink | Comments (0)

Gene therapy saves 2 children with adrenoleukodystrophy

6. November 2009 03:02
The ELA association and Zinedine Zidane, its emblematic ambassador, are proud to announce a world premiere: the results regaring the gene therapy in adrenoleukodystrophy conducted in France have just been published in the prestigious journal Science. Two children have been treated and their diseases have been halted. The children are doing well, which is unexpected for a disease destroying the brain in a few months. This discovery opens up treatment perspectives for numerous widespread diseases. [More]

Posted in: Child Health News | Medical Science News

Tags: , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

3. November 2009 06:58
Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2009. [More]

Posted in: Business / Finance | Pharmaceutical News

Tags: , , , , , , , , , , ,

Permalink | Comments (0)

FDA extends Acorda Therapeutics' Fampridine-SR PDUFA goal date

22. October 2009 06:52
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has extended the PDUFA goal date for its review of the New Drug Application (NDA) for Fampridine-SR to January 22, 2010. The original Prescription Drug User Fee Act (PDUFA) date for this priority review application was October 22, 2009. [More]

Posted in: Pharmaceutical News

Tags: , , , , , ,

Permalink | Comments (0)

Elan announces fiscal 2009 third-quarter results

21. October 2009 02:34
Elan Corporation, plc today reported its third quarter 2009 financial results. [More]

Posted in: Business / Finance

Tags: , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Postive vote from FDA Advisory Committee for Fampridine-SR 10

15. October 2009 00:14
Acorda Therapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs (PCNSD) Advisory Committee voted 12 to 1 that clinical data on Fampridine-SR 10 mg twice daily demonstrated substantial evidence of effectiveness as a treatment to improve walking in people with multiple sclerosis (MS) and voted 10 to 2 (1 abstention) that it is clinically meaningful and can be safe for use. [More]

Posted in: Pharmaceutical News

Tags: , , , , , , ,

Permalink | Comments (0)

Opexa Therapeutics' endeavor in the field of stem cell technology

24. September 2009 06:22
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that it has achieved its first technology transfer milestone in connection with the company’s recently announced exclusive stem cell agreement with Novartis, one of the world’s largest healthcare companies. The milestone was completed on schedule and triggers a payment of $500,000 to Opexa. [More]

Posted in: Medical Science News

Tags: , , , , , , ,

Permalink | Comments (0)

Researching the causes of Alzheimer's disease

23. September 2009 02:27
The standard explanation for what causes Alzheimer's is known as the amyloid hypothesis, which posits that the disease results from of an accumulation of the peptide amyloid beta, the toxic protein fragments that deposit in the brain and become the sticky plaques that have defined Alzheimer's for more than 100 years. [More]

Posted in: Medical Condition News

Tags: , , , , , , , , ,

Permalink | Comments (1)

Extension study data on Fampridine-SR drug

15. September 2009 07:55
Data from two long-term open-label extension studies of Fampridine-SR show that 86.0% of participants remained on therapy after a maximum treatment time of 15 months in study MS-F204EXT, and 69.5% remained on therapy after a maximum treatment time of 36 months in study MS-F203EXT. [More]

Posted in: Drug Trial News

Tags: , , , , , , , ,

Permalink | Comments (0)
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.